Navigation Links
Mindray Announces Second Quarter 2013 Financial Results
Date:8/5/2013

for the effects of share-based compensation and amortization of acquired intangible assets, all net of related tax impact.
  • Non-GAAP earnings per share represents non-GAAP net income divided by the number of shares used in computing basic and diluted earnings per share in accordance with GAAP, and excludes the impact of the declared dividends for the basic calculation.
  • EBITDA represents net income reported in accordance with GAAP, adjusted for the effect of interest income and expenses, provision of income taxes, depreciation and amortization.
  • The company computes its non-GAAP financial measures using the same consistent method from quarter to quarter. The company notes that these measures may not be calculated on the same basis of similar measures used by other companies. Readers are cautioned not to view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies, and should refer to the reconciliation of GAAP results with non-GAAP results for the three and six months ended June 30, 2012 and 2013, respectively, in the attached financial information.

    Cautionary Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including, without limitation, statements about Mindray's anticipated net revenues, non-GAAP net income and capital expenditure for 2013, our assumption of a corporate income tax rate of 15% applicable to the Shenzhen subsidiary, the impact of our recent acquisition of Zonare, our expectation that China is to continue to drive our overall growth and the emerging markets should gradually improve despite continued political and currency challenges in certain countries, our anticipation of uncertainty to persist in our North Ame
    '/>"/>

    SOURCE Mindray Medical International Limited
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related medicine technology :

    1. Mindray Files Annual Report on Form 20-F with the U.S. Securities and Exchange Commission
    2. Mindray Medical to Acquire Controlling Stake in Hangzhou Optcla Medical Instrument
    3. Mindray Announces First Quarter 2012 Financial Results
    4. Mindray Medical to Present at AACC Clinical Lab Expo 2012
    5. Mindray Medical Completes Acquisition of Dragonbios Orthopedics Business
    6. Mindray to Report Second Quarter 2012 Financial Results on August 6, 2012
    7. Mindray Announces Second Quarter 2012 Financial Results
    8. Mindray Medical to Participate in MEDICA 2012 in Dusseldorf, Germany
    9. Mindray Medical Announces Top Management Change
    10. Mindray DS USA, Inc. has Initiated a Voluntary Recall Affecting the A3/A5 Anesthesia Delivery System
    11. Mindray to Showcase Enhancements to DC-8 Ultrasound System at RSNA
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
    (Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
    (Date:1/15/2014)... BEACH GARDENS, Fla. , Jan. 15, 2014  In an unprecedented ... difficile and TB in ambulances and other transport vehicles, an advanced ... used by rescue personnel for the first time. ... in contact with these deadly pathogens, West Palm Beach ...
    Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
    ... Corporation (NASDAQ: HSKA ), a provider of ... today announced that Robert Grieve, Heska,s Chairman and CEO, will ... (PT), on March 14, 2012, Salon 1, Burgandy Track.  The ... Carlton, 1 Ritz Carlton Drive, Dana Point, California.  Dr. Grieve ...
    ... BETHESDA, Md., Feb. 23, 2012  Northwest Biotherapeutics (OTC.BB: NWBO) ... clinical trial sites open and recruiting across the United ... DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most ... milestone ahead of schedule, as the Company had projected ...
    Cached Medicine Technology:Heska to Present at the 24th Annual ROTH Conference 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 2NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection 3
    (Date:4/18/2014)... new medical-testing device is being prepped to enter ... improve diagnosis of certain diseases in remote areas, ... series of investigations aboard the International Space Station ... the space-tested concept of capillary flow to diagnose ... David Kelso, Ph.D., a researcher at Northwestern University ...
    (Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
    (Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
    (Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
    (Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
    Breaking Medicine News(10 mins):Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3
    ... Weight loss improves the sexual health of obese men with ... placed 31 obese men with type 2 diabetes on either ... diet meant to decrease calorie intake by 600 calories a ... to an easing of erectile dysfunction and improved sexual desire ...
    ... People living in a region of the southeastern United States ... higher rates of stroke deaths than the rest of the ... risk for sepsis, a severe illness in which bacteria overwhelms ... sepsis across the United States," said Dr. Henry Wang, associate ...
    ... University of Massachusetts Medical School have uncovered a novel ... immune response for malaria. Activation of this pathway appears ... by the immune system that may contribute to inflammation ... part in susceptibility for the most common and lethal ...
    ... , THURSDAY, Aug. 4 (HealthDay News) -- A ... comfortable using the clot-busting drug tissue plasminogen activator (tPA) to ... finds. An ischemic stroke is caused by blocked blood ... of neurology residents who say they,re comfortable using tPA rose ...
    ... have completed a comprehensive map of genetic mutations occurring ... The findings, reported in the Aug. 4 issue ... biological cause of the tumors, they say. To ... seven oligodendroglioma tissue samples, and focused attention on recurring ...
    ... the United States spend nearly four times as much dealing ... Most of the difference stems from the fact that Canadian ... multiple payers in the United States. These findings are ... -- the result of a research collaboration among Weill Cornell ...
    Cached Medicine News:Health News:U.S. 'Stroke Belt' May Also Be 'Sepsis Belt' 2Health News:Targeting innate immunity in malaria 2Health News:Targeting innate immunity in malaria 3Health News:More Neurology Residents Using Clot-Busting Drug for Stroke 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 2Health News:Johns Hopkins scientists map genes for common form of brain cancer 3Health News:US physician practices spend 4 times Canadian practices 2Health News:US physician practices spend 4 times Canadian practices 3
    Cholesterol/HDL with 200 tests....
    Intended for the in vitro precipitation of very low density and low density lipoproteins in serum or plasma. Single vial, dry powder precipitating reagent. Total cholesterol reagent not included....
    ... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
    ... the quantitative determination of ... vials, dry powder reagents. ... NADPH to eliminate interferences ... Reaction: Enzymatic, endpoint. Wavelength: ...
    Medicine Products: